Please login to the form below

Not currently logged in
Email:
Password:

BMS lobbying spend reaches USD 2.8m

Bristol-Myers Squibb spent over USD 2.8m in H1 2007 to lobby the US Federal government over patent protection

US-headquartered pharmaceutical company Bristol-Myers Squibb (BMS) spent over USD 2.8m in H1 2007 to lobby the US Federal government over patent protection.

The company continues to lobby for patent protection for the pharmaceutical industry, free trade agreements and more funding for the FDA, according to a form posted online by the Senate's public records office on 10 October 2007.

In early September 2007, the House approved a patent reform bill intended to reduce patent litigation, improve patent quality, increase information available to patent examiners and establish a post-approval patent re-evaluation process.

While technology and financial services firms supported the legislation, pharmaceutical and biotechnology companies claim it will weaken patent protection by reducing infringement penalties and permitting post-approval challenges to patents.

The Senate is also considering similar legislation.

BMS has also been lobbying the Agriculture and Commerce departments and the US Trade Representative's office.

GlaxoSmithKline (GSK) has already instigated a lawsuit which seeks an injunction against the US Patent and Trademark Office (PTO) to stop them from bringing into effect new rules as of 1 November 2007. GSK says the new law will stifle innovation.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics